Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2006-02-21
2006-02-21
Wilson, Michael C. (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C536S123100
Reexamination Certificate
active
07002027
ABSTRACT:
The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.
REFERENCES:
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5279833 (1994-01-01), Rose
patent: 5283185 (1994-02-01), Epand et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552309 (1996-09-01), March
patent: 5554386 (1996-09-01), Groman et al.
patent: 5578475 (1996-11-01), Jessee
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/19768 (1993-10-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/06922 (1994-03-01), None
patent: WO 94/06923 (1994-03-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 97/27599 (1997-07-01), None
Eck and Wilson, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, pp. 77-101, 1995.
Verma et al. Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
Ross et al. Human Gene therpay, vol. 7 pp. 1781-1790, Sep. 1996.
Marshall, et al. Science, vol. 269, pp. 1050-1055, Aug. 25, 1995.
Aungst et al. Int. J. Pharm., vol. 53, pp. 227-235, 1993.
Wills et al., Human gene therapy, vol. 5, pp. 1079-1088, 1994.
Takahashi et al. Proc. Natl. Acad. Sci., USA, vol. 88, pp. 5257-5261, 1991.
Abe, A. et al., “Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector,”P.S.E.B.M.203:354-359 (1993).
Arteaga, C.L. et al., “Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice,”Cancer Research56:1098-1103 (1996).
Banerjee, A. et al., “Changes in Growth and Tumorgenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types by Microcell Transfer of Chromosome 13,”Cancer Research52:6297-6304.
Bass, C. et al., “Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo,”Cancer Gene Ther.2(2) :97-104 (1995).
Blixt, Y. et al., “Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer,”Arch. Virol.129:265-277 (1993).
Boulikas, “Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets,”Anticancer Research17:1471-1506 (1997).
Brewster, S.F. et al., “Gene Therapy in Urological Oncology: Principles, Strategies and Potential,”Eur. Urol.25:177-182 (1994).
Cairns, P. et al., “Loss of heterozygosity at the RB locus is frequent & cor-relates with muscle invastion in bladder carcinoma,”Oncogene6:2305-2309 (1991).
Cooper, M.J. et al., “Safety-modified episomal vectors for human gene therapy,”Proc. Natl. Acad. Sci. U.S.A.94:6450-6455 (1997).
Curiel, D.T. et al., “Adenovirus enhancement of transferrin-polylysine-mediated gene delivery,”Proc. Natl. Acad. Sci. U.S.A.88:8850-8854 (1991).
Dalesandro, J. et al., “Cardiac and Pulmonary Replacment,”J. Thoracic Cardio. Surg.111(2) :416-422 (1996).
Fujimoto, K. et al., “Frequent Association of p53 Gene Mutation in Invasive Bladder Cancer,”Cancer Research52:1393-1398 (1992).
Ginsberg, H.S. et al., “Role of early region 3 (E3) in pathogenesis of adenovirus disease,”Proc. Natl. Acad. Sci. U.S.A.86:3823-3827 (1989).
Good, N.E. et al., “Hydrogen Ion Buffers for Biological Research,”Biochemistry5(2) :467-477 (1996).
Goodrich, D.W. et al., “Expression of the Retinoblastoma Gene Product in Bladder Carcinoma Cells Associates with a Low Frequency of Tumor Formation,”Cancer Research52:1968-1973 (1992).
Greney, H. et al., “Characterizatino of Imidazoline Binding Protein(s) Solubilized from Human Brainstem: Studies with [3H] Idazoxan and [3H] Clonidine,”Neurochem. Int.25(2) :183-191 (1994).
Greenberg, R. et al., “Intravesical AD32 (N-Trifluoroacetyladriamycin-14-Valerate) in the Treatment of Patients with Refractory Bladder Carcinoma—Clinical Efficacy, Pharmacology, and Safety,”Proc. Am. Urol. Assoc.153 Supp 233A:19 (1995).
Hemström, C. et al., “Gene Product of Region E4 of Adenovirus Type 5 Modulates Accumulation of Certain Viral Polypeptides,”J. Virol.62(9) :3258-3264 (1988).
Huang, S. et al., “A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product,”Nature350:160-162 (1991).
Ji, W. et al., “Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA,”J. Viral Hep.4:167-173 (1997).
Kaneda, Y. et al., “Prevention of Restenosis by Gene Therapy,”Annals N.Y. Acad. Sci.811:299-310 (1997).
Koc, O.N. et al., “Transfer of Drug Resistance Genes Into Hemotopoietic Progenitors to Improve Chemotherapy Tolerance,”Sem. Oncol.23(1) :46-64 (1996).
Lee, R.J. et al., “Lipidic Vector Systems for Gene Transfer,”Crit. Rev. Ther. Drug Carrier Sys.14(2) :173-206 (1997).
Li, Q. et al., “Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy,”Hum. Gene. Ther.4:403-409 (1993).
Makarov, S.S. et al., “Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA,”Proc. Natl. Acad. Sci. U.S.A.93:402-406 (1996).
Marshall, E., “Gene Therapy's Growing Pains,”Science269:1050-1055 (1995).
Miller, N. et al., “Targeted vectors for gene therapy,”FASEB J.9:190-199 (1995).
Monson, F.C. et al., “Indigocarmine as a quantitative indicator of urothelial integrity,”J. Urol.145:842-845 (1991).
Morris, B.D. et al., “Adenoviral-mediated gene transfer to bladder in vivo,”J. Urol.152:506-509 (1994).
Murayama, Y. et al., “Antisense Oligonucleotides to p53 Tumor Suppressor Suppress the Induction of Apoptosis by Epidermal Growth Factor in NCI-H 596 Human Lung Cancer Cells,”Antisense Nucl. Acid Drug Devel.7:109-114 (1997).
Niidome, T. et al., “Binding of Cationic α-Helical Peptides to Plasmid DNA and Their Gene Transfer Abilities into Cells,”J. Biol. Chem.272(24) :15307-15312.
Nolta, J.A. et al., “Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice,”Proc. Natl. Acad. Sci. U.S.A.93:2414-2419 (1996).
Parsons, C.L. et al., “Bladder surface glycosaminoglycans: an epithelial permeability barrier,”J. Urol.143:139-142 (1990).
Pinnaduwage, P. et al., “Use of quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells,”Biochim. Biophys. Acta985:33-37 (1989).
Plank, C. et al., “The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems,”J. Biol. Chem.269(17) :12918-12924 (1994).
Raper, S.E. et al., “Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia,”Annals Surgery223(2) :116-126 (1996).
Rosenberg, S.A., “The Immunotherapy and Gene Therapy of Cancer,”J. Clin. Oncol.10(2) :180-199 (1992).
Sandberg, J.W. et al., “Improving Access to I
Engler Heidrun
Nagabhushan Tattanahalli L.
Youngster Stephen Kenneth
Canji Inc.
Schering Corporation
Townsend and Townsend / and Crew LLP
Wilson Michael C.
LandOfFree
Compositions and methods for therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3635830